$BXP

LABELLE MICHAEL E sold $1.7M of BXP

LABELLE MICHAEL E (EVP and CFO) sold 26,113 shares of BXP, Inc. (BXP) at an average of $66.35 ($66.05–$67.02, $1.73M total) across 2 trades on 2026-06-09.

Original reporting
SEC EDGAR · LABELLE MICHAEL E
Published Jun 10, 2026, 2:25 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 10, 2026, 2:28 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$BXP
Neutral
medium confidence
Mentioned
$BXP
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BXPNeutralLow
01

Why it matters

Traders may monitor for follow-on insider activity or correlate with other upcoming company catalysts, but the disclosure alone does not change BXP’s operating outlook.

02

Market read

A CFO open-market sale totaling ~$1.73M is newly disclosed; it may slightly affect sentiment but lacks fundamental new information.

03

What to watch

The filing notes no pre-arranged 10b5-1 plan, which some traders may interpret as less “mechanical,” but the article provides no additional context (e.g., option exercises, tax planning) to confirm intent.

Relevance 6/10Novelty 6/10Timing: Filed June 10; sale executed June 9

Background

The article is an SEC Form 4 insider transaction disclosure for BXP, reporting sales by the EVP & CFO.

Company-level read

Ticker impact

$BXPNeutralMedium confidence
Context

BXP CFO sold 26,113 shares in open-market transactions totaling about $1.73M, disclosed via SEC Form 4 on June 10.

Expected impact

Low likelihood of a sustained price move; any reaction is likely short-lived unless paired with other company-specific catalysts.

Evidence & confidence

The filing is a primary-source insider transaction, but it does not include new fundamentals (earnings, guidance, deals, or regulatory actions). The absence of a stated 10b5-1 plan can add some interpretive noise, yet the disclosed value is not large enough to imply a major corporate event.

Market effects

Minimal—this is company-specific insider activity without sector-wide signal.

None indicated.

None indicated.

Counterpoint

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs rather than bearish expectations; the modest dollar amount supports that view.

Key entities

  • BXP, Inc.

    Real estate investment trust; subject of the Form 4 insider sale by its EVP & CFO.

  • LABELLE MICHAEL E

    EVP and CFO who sold 26,113 shares on June 9.

Related articles

$BXPMed

BXP, Inc. Q2 2026 Earnings Call Summary

Strategic Performance and Market Dynamics BXP delivered a strong second quarter, exceeding FFO guidance by $0.08 and raising the 2026 midpoint by $0.05, driven by faster-than-expected leasing and occupancy gains. Management attributes the leasing momentum to a 'very healthy environment' for premier workplaces, noting that AI is acting as a significant tailwind by driving space expansions and upgrades among tech and professional service firms.

$BXPMed

BXP Secures $1.2B Construction Loan for 343 Madison Avenue Office Tower – Commercial Observer

BXP announced it secured a $1.2B construction loan for its 930,000 sq ft, 46-story office tower at 343 Madison Ave in Midtown, with a four-year term plus a one-year extension option, from Wells Fargo, Bank of America Securities, BNY Mellon and J.P. Morgan. Completion is set for 2029; the project is 50% pre-leased. BXP reported Q2 2026 FFO of $283.4M ($1.78/share) and revenue of $895.7M.

$BXPMed

BXP Selling 7 Times Square Ground Lease

Boston Properties (BXP) is marketing the 7 Times Square ground lease via Eastdil Secured, hiring Will Silverman and Gary Phillips. BXP expects proceeds of $700 million to $750 million, with bids due soon. The 1.2M sq ft tower has a 99-year lease and is 91% occupied. The deal would test Times Square office demand.

$BXPMed

Q3 Financial Results 2025-26

Beximco Pharmaceuticals PLC (AIM: BXP) reported unaudited Q3 and nine-month results ended 31 March 2026. For nine months, net sales rose 13.1% to BDT 41,428.0m (£256.9m) and profit after tax increased 34.0% to BDT 7,048.6m (£43.7m). In Q3, net sales grew 8.1% to BDT 13,627.8m (£84.5m) and PAT rose 30.6% to BDT 2,254.4m (£14.0m).